<DOC>
	<DOC>NCT00113971</DOC>
	<brief_summary>The goal of this study is to evaluate how epratuzumab is processed by the body (pharmacokinetics) and whether 2 dose levels of epratuzumab are safe and effective in patients with SLE.</brief_summary>
	<brief_title>Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description>This study is planned to provide information on how the body processes epratuzumab and how epratuzumab affects the body when epratuzumab is given once weekly for 4 weeks in a row at one of 2 different dose levels. Additional information will be obtained related to the natural variability of disease activity in SLE patients.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Has SLE by American College of Rheumatology revised criteria (meets &gt;/= 4 criteria) Has had SLE for at least 6 months prior to study entry Has at least one elevated autoantibody level at study entry Has moderately active SLE disease at study entry in any body/organ system (Full criteria not present here due to length of considerations. The protocols should be consulted regarding the complete list of entry criteria.) Exclusion criteria: Active Severe Lupus as defined by BILAG Index Level A in any body system or organ Allergy to human antibodies or Murine Prior therapy with other antiB cell antibodies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>study of epratuzumab in systemic lupus erythematosus</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>SLE</keyword>
</DOC>